BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 26831716)

  • 21. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
    Yang Q; Titus MA; Fung KM; Lin HK
    J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines.
    Kawabata R; Oie S; Takahashi M; Kanayama H; Oka T; Itoh K
    Int J Oncol; 2011 Jun; 38(6):1489-500. PubMed ID: 21455575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
    Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
    Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of neurotensin receptor 1 selectively sensitizes prostate cancer to ionizing radiation.
    Valerie NC; Casarez EV; Dasilva JO; Dunlap-Brown ME; Parsons SJ; Amorino GP; Dziegielewski J
    Cancer Res; 2011 Nov; 71(21):6817-26. PubMed ID: 21903767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carbidopa abrogates L-dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression.
    Wafa LA; Cheng H; Plaa N; Ghaidi F; Fukumoto T; Fazli L; Gleave ME; Cox ME; Rennie PS
    Int J Cancer; 2012 Jun; 130(12):2835-44. PubMed ID: 21780103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L; Giocanti N; Hennequin C; Favaudon V
    Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MLN8054, a small molecule inhibitor of aurora kinase a, sensitizes androgen-resistant prostate cancer to radiation.
    Moretti L; Niermann K; Schleicher S; Giacalone NJ; Varki V; Kim KW; Kopsombut P; Jung DK; Lu B
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1189-97. PubMed ID: 21514073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth.
    Liu S; Yuan Y; Okumura Y; Shinkai N; Yamauchi H
    Biochem Biophys Res Commun; 2010 Apr; 394(2):297-302. PubMed ID: 20206136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
    Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
    Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen receptor signaling regulates DNA repair in prostate cancers.
    Polkinghorn WR; Parker JS; Lee MX; Kass EM; Spratt DE; Iaquinta PJ; Arora VK; Yen WF; Cai L; Zheng D; Carver BS; Chen Y; Watson PA; Shah NP; Fujisawa S; Goglia AG; Gopalan A; Hieronymus H; Wongvipat J; Scardino PT; Zelefsky MJ; Jasin M; Chaudhuri J; Powell SN; Sawyers CL
    Cancer Discov; 2013 Nov; 3(11):1245-53. PubMed ID: 24027196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
    Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
    Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nuclear Transglutaminase 2 interacts with topoisomerase II⍺ to promote DNA damage repair in lung cancer cells.
    Lei X; Cao K; Chen Y; Shen H; Liu Z; Qin H; Cai J; Gao F; Yang Y
    J Exp Clin Cancer Res; 2021 Jul; 40(1):224. PubMed ID: 34225780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
    Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
    Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
    Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
    Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgen-dependent regulation of Her-2/neu in prostate cancer cells.
    Berger R; Lin DI; Nieto M; Sicinska E; Garraway LA; Adams H; Signoretti S; Hahn WC; Loda M
    Cancer Res; 2006 Jun; 66(11):5723-8. PubMed ID: 16740710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.
    Attardi BJ; Burgenson J; Hild SA; Reel JR
    Mol Cell Endocrinol; 2004 Jul; 222(1-2):121-32. PubMed ID: 15249132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
    Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
    Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.